A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.

ClinicalTrials.gov processed this data on September 12, 2023. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED - HAS RESULTS
 (See Contacts and Locations)
Verified September 2023 by GlaxoSmithKline

Sponsor

GlaxoSmithKline

Information Provided by (Responsible Party)

GlaxoSmithKline

Clinicaltrials.gov Identifier

NCT05045144
Other Study ID Numbers: 214709
First Submitted: September 6, 2021
First Posted: September 16, 2021
Results First Posted: October 5, 2023
Last Update Posted: October 5, 2023
Last Verified: September 2023
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Respiratory Syncytial Virus Infections
  • Combination Product: RSVPreF3(120 μg)
  • Combination Product: Flu Quadrivalent influenza vaccine (15 μg HA)
  • Combination Product: Placebo

Study Design

Study TypeInterventional
Actual Enrollment1586 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingQuadruple
Primary PurposePrevention
Official TitleA Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.
Study Start DateOctober 26, 2021
Actual Primary Completion DateJune 6, 2022
Actual Study Completion DateJune 6, 2022

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • RSV lot1 Group
    • Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
  • Combination Product: RSVPreF3(120 μg)
    • A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
  • RSV lot2 Group
    • Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
  • Combination Product: RSVPreF3(120 μg)
    • A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
  • RSV lot3 Group
    • Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
  • Combination Product: RSVPreF3(120 μg)
    • A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
  • RSV+Flu pooled Group
    • Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181).

      The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines.
  • Combination Product: Flu Quadrivalent influenza vaccine (15 μg HA)
    • Flu+Placebo Group
      • Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181).

        This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group.
    • Combination Product: Flu Quadrivalent influenza vaccine (15 μg HA)
      • Combination Product: Placebo

        Outcome Measures

        Primary Outcome Measures

        1. Percentage of Participants Reporting Solicited Administration Site Events in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group [From Day 1 to Day 7 (including Day 7)]
          Assessed solicited administration site events include pain, erythema and swelling. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        2. Percentage of Participants Reporting Solicited Systemic Events in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group [From Day 1 to Day 7 (including Day 7)]
          Assessed solicited systemic events include fatigue, headache, gastrointestinal (GI) symptoms (nausea, vomiting, diarrhea, abdominal pain) and fever. The preferred location for measuring temperature was the oral cavity. Fever was defined as temperature equal to or above (≥) 38.0 °C/ 100.4°F. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        3. Percentage of Participants Reporting Unsolicited Adverse Events (AEs) in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group [From Day 1 to Day 30 (including Day 30)]
          An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        4. Percentage of Participants Reporting Serious Adverse Events (SAEs) in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group [From Day 1 to Day 30 (including Day 30)]
          An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results i+F2n abnormal pregnancy outcomes. This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        5. Percentage of Participants Reporting SAEs in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group [From first vaccination up to study end (Day 1 to Day 181)]
          An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes.This objective analyzed the safety and reactogenicity of RSV MAT vaccine when given alone (pooled lots) or co-administered with Flu D-QIV. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        6. RSV MAT Immunoglobulin G (IgG) Enzyme-Linked Immunosorbent Assay (ELISA) Concentrations for Participants in RSV lot1, RSV lot2 and RSV lot3 Groups at Day 31 [At Day 31]
          Serological assays for the determination of IgG antibodies against RSV MAT were performed by ELISA. RSV MAT IgG concentrations were expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EU/mL). As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze RSV MAT IgG ELISA concentrations, in order to demonstrate the lot-to-lot consistency of the vaccine lots.
        7. Flu D-QIV Haemagglutinin Inhibition (HI) Antibody Titers Against 3 Influenza Strains for Participants in Flu+Placebo Group and RSV+Flu Pooled Group at Day 31 [At Day 31]
          Flu D-QIV HI antibody titers against 3 influenza strains (A/Tasmania/503/2020 (H3N2) IVR-221; B/Washington/02/2019; B/Phuket/3073/2013) were expressed as geometric mean titers (GMTs), as assessed by HI assay. This objective analyzed the humoral immune response to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine in terms of antibody titers against 3 influenza strains. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu Group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.

        Secondary Outcome Measures

        1. RSV A Neutralizing Antibody Titers for Participants in RSV Pooled Group and RSV+Flu Pooled Group at Day 1 and Day 31 [At Day 1 and Day 31]
          Serological assays for the determilnation of antibodies against RSV A were performed by neutralization assay. RSV A neutralizing antibody titers were expressed as geometric mean titers (GMTs), in serum dilution inducing 60% inhibition in plaque forming units (ED60). This objective analyzed the humoral immune response of RSV MAT vaccine when given alone and co-administered with Flu D-QIV in terms of RSV A neutralizing antibody. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        2. Seroconversion Rate (SCR) to Flu D-QIV HI Antibody Titers Against 3 Influenza Strains for Participants in Flu+Placebo Group and RSV+Flu Pooled Group at Day 31 [At Day 31]
          The SCR was defined as the percentage of participants with: a Day 1 (pre-vaccination) serum anti-HI titer <1:10 and a Day 31 (post-vaccination) serum anti-HI titer ≥1:40, or a Day 1 (pre-vaccination) serum anti-HI titer ≥ 1:10 and a fold increase (post/pre) ≥ 4 at Day 31. The 3 influenza strains assessed were: A/Tasmania/503/2020 (H3N2) IVR-221; B/Washington/02/2019 and B/Phuket/3073/2013. This objective analyzed the seroconversion rate to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        3. RSV B Neutralizing Antibody Titers for Participants in RSV Pooled Group and RSV+Flu Pooled Group at Day 1 and Day 31 [At Day 1 and Day 31]
          Serological assays for the determination of antibodies against RSV B were performed by neutralization assay. RSV B neutralizing antibody titers were expressed as GMTs, in ED60. This objective analyzed the humoral immune response of RSV MAT vaccine when given alone and co-administered with Flu D-QIV in terms of RSV B neutralizing antibody. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        4. RSV MAT IgG Concentrations for Participants in RSV Pooled Group and RSV+Flu Pooled Group at Day 1 and Day 31 [At Day 1 and Day 31]
          Serological assays for the determination of IgG antibodies against RSV MAT were performed by ELISA. RSV MAT IgG concentrations were expressed as GMCs, in EU/mL. This objective analyzed the humoral immune response of RSV MAT vaccine when given alone and co-administered with Flu D-QIV in terms of RSV MAT IgG concentrations. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV and RSV+Flu groups, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        5. Flu D-QIV HI Antibody Titers Against 3 Influenza Strains for Participants in Flu+Placebo Group and RSV+Flu Pooled Group at Day 1 and Day 31 [At Day 1 and Day 31]
          Flu D-QIV HI antibody titers against 3 influenza strains (A/Tasmania/503/2020 (H3N2) IVR-221;B/Washington/02/2019; B/Phuket/3073/2013) were expressed as geometric mean titers (GMTs), as assessed by HI assay. This objective analyzed the humoral immune response to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine in terms of antibody titers against 3 influenza strains. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu Group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        6. Seroprotection Rate (SPR) to Flu D-QIV HI Antibody Titers for Participants in Flu+Placebo Group and RSV+Flu Pooled Group at Day 1 and Day 31 [At Day 1 and Day 31]
          SPR was measured by the percentage of participants achieving an HI antibody titer ≥1:40. This objective analyzed the seroprotection rate to the Flu D-QIV vaccine when given alone and co-administered with RSV MAT vaccine. As pre-specified in protocol, data reported in this outcome measure was presented for the pooled RSV+Flu Group and Flu+Placebo Group, since minimal differences were expected between participants who received different RSV lots of the vaccine.
        7. RSV A Neutralizing Antibody Titers for Participants in RSV lot1, RSV lot2 and RSV lot3 Groups at Day 1 and Day 31 [At Day 1 and Day 31]
          Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. RSV A neutralizing antibody titers were expressed as GMTs, in ED60. As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze the humoral immune response of RSV A neutralizing antibody titers, in order to demonstrate the lot-to-lot consistency of the vaccine lots.
        8. RSV B Neutralizing Antibody Titers for Participants in RSV lot1, RSV lot2 and RSV lot3 Groups at Day 1 and Day 31 [At Day 1 and Day 31]
          Serological assays for the determination of antibodies against RSV B were performed by neutralization assay. RSV B neutralizing antibody titers were expressed as GMTs, in ED60. As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze the humoral immune response of RSV B neutralizing antibody titers, in order to demonstrate the lot-to-lot consistency of the vaccine lots.
        9. RSV MAT IgG Concentrations for Participants in RSV lot1, RSV lot2 and RSV lot3 Groups at Day 1 and Day 31 [At Day 1 and Day 31]
          Serological assays for the determination of IgG antibodies against RSV MAT were performed by ELISA. RSV MAT IgG concentrations were expressed as GMCs, in EU/mL. As pre-specified in protocol, data reported in this outcome measure was presented only for individual RSV lot groups (RSV lot1, RSV lot2, RSV lot3), as the purpose was to analyze the RSV MAT IgG concentration, in order to demonstrate the lot-to-lot consistency of the vaccine lots.

        Eligibility Criteria

        Ages Eligible for Study 18 Years to 49 Years (Adult)
        Sexes Eligible for Study Female
        Accepts Healthy Volunteers Yes
        Inclusion Criteria
        • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
        • Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study specific procedure.
        • Healthy female participants; as established by medical history and clinical examination, aged 18 to 49 years at the time of the first study intervention administration.
        • Female participants of childbearing potential may be enrolled in the study, if the participant:
        • has practiced adequate contraception for 1 month prior to study intervention administration, and
        • has a negative pregnancy test on the day of study intervention administration, and
        • has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration.
        • No local condition precluding injection in both left and right deltoid muscles.
        Exclusion Criteria
        • Medical conditions
        • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions;
        • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination;
        • Current autoimmune disorder, for which the participant has received immune-modifying therapy within 6 months, before study vaccination;
        • Hypersensitivity to latex;
        • Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions, as determined by physical examination or medical history that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study;
        • Significant or uncontrolled psychiatric illness;
        • Recurrent history or uncontrolled neurological disorders or seizures;
        • Documented HIV-positive participant;
        • Body mass index > 40 kg/m^2;
        • Any clinically significant* hematological parameter and/or biochemical laboratory abnormality.
        • *The investigator should use his/her clinical judgment to decide which abnormalities are clinically significant.
        • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
        • Prior/Concomitant therapy
        • Use of any investigational or non-registered product other than the study intervention(s) during the period starting 30 days before study intervention (Day -29 to Day 1), or planned use during the study period;
        • Administration of long-acting immune-modifying drugs at any time during the study period;
        • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the study intervention or planned administration during the study period;
        • Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s). For corticosteroids, this will mean prednisone 5 mg/day, or equivalent. Inhaled and topical steroids are allowed;
        • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after the vaccination dose;
        • Administration of a seasonal influenza vaccine during the 6 months preceding entry into the study;
        • Previous experimental vaccination against RSV.
        • Prior/Concurrent clinical study experience Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product;
        • Other exclusions
        • Pregnant or lactating female;
        • Female planning to become pregnant or planning to discontinue contraceptive precautions;
        • Alcoholism or substance use disorder within the past 24 months based on the presence of two or more of the following abuse criteria: hazardous use, social/interpersonal problems related to use, neglected major roles to use, withdrawal tolerance, use of larger amounts or longer, repeated attempts to quit or control use, much time spent using, physical or psychological problems related to use, activities given up to use, craving;
        • Any study personnel or their immediate dependents, family, or household members.

        Contacts and Locations

        Sponsors and Collaborators GlaxoSmithKline
        Locations
        • GSK Investigational Site | West Palm Beach, Florida, United States, 33409
        • GSK Investigational Site | Stockbridge, Georgia, United States, 30281
        • GSK Investigational Site | Peoria, Illinois, United States, 61614
        • GSK Investigational Site | Springfield, Missouri, United States, 65802
        • GSK Investigational Site | Seattle, Washington, United States, 98105
        • GSK Investigational Site | Surrey, British Columbia, Canada, V3S 2N6
        • GSK Investigational Site | Vancouver, British Columbia, Canada, V6Z 2T1
        • GSK Investigational Site | Truro, Nova Scotia, Canada, B2N 1L2
        • GSK Investigational Site | London, Ontario, Canada, N5W 6A2
        • GSK Investigational Site | Sarnia, Ontario, Canada, N7T 4X3
        • GSK Investigational Site | Toronto, Ontario, Canada, M9W 4L6
        • GSK Investigational Site | Mirabel, Quebec, Canada, J7J 2K8
        • GSK Investigational Site | Pointe-Claire, Quebec, Canada, H9R 4S3
        • GSK Investigational Site | Sherbrooke, Quebec, Canada, J1L 0H8
        • GSK Investigational Site | St-Charles-Borromée, Quebec, Canada, J6E 2B4
        • GSK Investigational Site | Quebec, Canada, G1W 4R4
        • GSK Investigational Site | Espoo, Finland, 02230
        • GSK Investigational Site | Helsinki, Finland, 00100
        • GSK Investigational Site | Helsinki, Finland, 00930
        • GSK Investigational Site | Jarvenpaa, Finland, 04400
        • GSK Investigational Site | Kokkola, Finland, 67100
        • GSK Investigational Site | Pori, Finland, 28100
        • GSK Investigational Site | Seinajoki, Finland, 60100
        • GSK Investigational Site | Tampere, Finland, 33100
        • GSK Investigational Site | Turku, Finland, 20520
        • GSK Investigational Site | Gyeonggi-do, Korea, Republic of, 15355
        • GSK Investigational Site | Seoul, Korea, Republic of, 07441
        • GSK Investigational Site | Seoul, Korea, Republic of, 08308
        • GSK Investigational Site | Alcorcón/Madrid, Spain, 28922
        • GSK Investigational Site | Madrid, Spain, 28006
        • GSK Investigational Site | Madrid, Spain, 28034
        • GSK Investigational Site | Madrid, Spain, 28041
        • GSK Investigational Site | Madrid, Spain, 28046
        • GSK Investigational Site | Majadahonda (Madrid), Spain, 28222
        • GSK Investigational Site | Santiago de Compostela, Spain, 15706
        • GSK Investigational Site | Valencia, Spain, 46015
        Investigators

          Study Documents (Full Text)

          More Information

          Additional Relevant MeSH Terms

          • Influenza, Human
          • Respiratory Syncytial Virus Infections
          • Respiratory Tract Infections
          • Infections
          • Orthomyxoviridae Infections
          • RNA Virus Infections
          • Virus Diseases
          • Respiratory Tract Diseases
          • Pneumovirus Infections
          • Paramyxoviridae Infections
          • Mononegavirales Infections